Digilab BioVisioN GmbH closes cooperation agreement with Boehringer Ingelheim
06-Apr-2006
Within the project Digilab BioVisioN will analyze the quantitative peptide content of biological samples for the German pharmaceutical company. Using the patent-protected Peptidomics®-Technologies of Digilab BioVisioN, differences in peptide patterns are sought in order to identify new biomarkers. Further details of the project were not released.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.